Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation
Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation
复制标题
早期转移性前列腺癌的治疗：局部治疗和放射治疗（有或没有免疫调节）的评估
DOI：
10.1530/erc-21-0073
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
K. Yamoah
中科院分区：
文献类型：
--
作者：
M. Sandoval;A. Dohm;K. Yamoah
The current standard for the management of locally advanced and early stage metastatic prostate cancer relies on a backbone of androgen deprivation therapy (ADT) combined with radiotherapy (RT), a regimen that at a glance appears relatively straightforward. The emergence of newer diagnostic, genomic and imaging modalities have allowed for better disease risk-stratification and opened avenues for the development of more patient-centered treatment strategies. This review aims to highlight the central role of RT as part of a multi-modal approach and discuss established and emerging data for the management of locally advanced disease, biochemical recurrence, and oligometastatic disease, as well as the use of immunotherapies and radio-isotopes. This review will also briefly discuss ongoing clinical trials that provide new insights into the paradigm shift in the management of locally advanced prostate cancer.
